CLINDA-T SOLUTION

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

CLINDAMYCIN (CLINDAMYCIN PHOSPHATE)

Διαθέσιμο από:

BAUSCH HEALTH, CANADA INC.

Φαρμακολογική κατηγορία (ATC):

D10AF01

INN (Διεθνής Όνομα):

CLINDAMYCIN

Δοσολογία:

1%

Φαρμακοτεχνική μορφή:

SOLUTION

Σύνθεση:

CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 1%

Οδός χορήγησης:

TOPICAL

Μονάδες σε πακέτο:

250ML

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

ANTIBIOTICS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0105830004; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2021-03-03

Αρχείο Π.Χ.Π.

PRODUCT MONOGRAPH
PR
CLINDA-T
®
Clindamycin
Phosphate Topical Solution,
USP
Clindamycin
1% w/v
ANTIBIOTIC
BAUSCH HEALTH, CANADA INC.
DATE OF REVISION: February 15, 2022
2150 St-Elzear Blvd. West
Laval, Quebec
H7L 4A8
Control No. 260555

CLINDA-T is a registered trademark of Bausch Health, Canada Inc.
_ Pr_
_CLINDA-T_
_®_
_ Product Monograph _
_Page 2 of 19_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS.............................................................................................
3
WARNINGS AND PRECAUTIONS
............................................................................
4
ADVERSE REACTIONS
.............................................................................................
6
DRUG INTERACTIONS
.............................................................................................
7
DOSAGE AND ADMINISTRATION
..........................................................................
8
OVERDOSAGE...........................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 9
STORAGE AND STABILITY
.....................................................................................
9
DOSAGE FORMS, COMPOSITION AND
PACKAGING...........................................10
PART II: SCIENTIFIC INFORMATION
.........................................................................
11
PHARMACEUTICAL INFORMATION
.....................................................................11
DETAILED PHARMACOLOGY
................................................................................12
MICROBIOLOGY
.................................................................................